(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-3.32%) $1.920
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
@ $11.85
Utstedt: 14 feb 2024 @ 19:14
Avkastning: -20.84%
Forrige signal: feb 13 - 18:38
Forrige signal:
Avkastning: 1.28 %
Live Chart Being Loaded With Signals
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK...
Stats | |
---|---|
Dagens volum | 42 667.00 |
Gjennomsnittsvolum | 143 247 |
Markedsverdi | 237.27M |
EPS | $0 ( 2024-03-12 ) |
Neste inntjeningsdato | ( $-1.160 ) 2024-05-14 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -2.37 |
ATR14 | $0.0330 (0.35%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-05 | Calkins Daniel | Sell | 6 | Common Stock |
2024-03-25 | Calkins Daniel | Sell | 25 | Common Stock |
2024-03-20 | Calkins Daniel | Sell | 55 | Common Stock |
2024-03-18 | Gagnon Robert E. | Sell | 283 | Common Stock |
2024-03-19 | Gagnon Robert E. | Sell | 130 | Common Stock |
INSIDER POWER |
---|
50.22 |
Last 99 transactions |
Buy: 1 037 036 | Sell: 241 539 |
Volum Korrelasjon
Verastem Inc Korrelasjon
10 Mest positive korrelasjoner | |
---|---|
PXLW | 0.908 |
CVCY | 0.885 |
IMAB | 0.884 |
SRRK | 0.882 |
ADXN | 0.88 |
SHYF | 0.875 |
FOXA | 0.872 |
VIRC | 0.863 |
CRTO | 0.863 |
FLUX | 0.86 |
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Verastem Inc Korrelasjon - Valuta/Råvare
Verastem Inc Økonomi
Annual | 2023 |
Omsetning: | $0 |
Bruttogevinst: | $-62 000.00 (0.00 %) |
EPS: | $-3.96 |
FY | 2023 |
Omsetning: | $0 |
Bruttogevinst: | $-62 000.00 (0.00 %) |
EPS: | $-3.96 |
FY | 2022 |
Omsetning: | $2.60M |
Bruttogevinst: | $2.48M (95.45 %) |
EPS: | $-4.58 |
FY | 2021 |
Omsetning: | $2.05M |
Bruttogevinst: | $2.05M (100.00 %) |
EPS: | $-0.464 |
Financial Reports:
No articles found.
Verastem Inc
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of VS-6766 and in combination with defactinib, an oral small molecule inhibitor of focal adhesion kinase (FAK) in patients with recurrent low grade serous ovarian cancer; and RAMP 202, which is in Phase 2 trial to evaluate the safety of VS-6766 in combination with defactinib in patients with KRAS and BRAF mutant non-small cell lung cancer following treatment with a platinum-based regimen and immune checkpoint inhibitor. Verastem, Inc. has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing VS-6766; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic and prophylactic uses in humans. In addition, it has clinical collaboration agreement with Amgen, Inc. to evaluate the combination of VS-6766 with Amgen's KRAS-G12C inhibitor LUMAKRASTM which in Phase 1/2 trial entitled RAMP 203. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.